Cel-Sci Corp., of Vienna, Va., in an 8-K filing reported that although it believed the response submitted to the FDA in November addressed each of the deficiencies identified by the agency and outlined in a partial clinical hold letter, the FDA issued an incomplete response to the hold letter.